Cargando…

Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile

(1) Background: Biomarkers might play a significant role in predicting the clinical outcomes of patients with ovarian cancer. By analyzing lipid metabolism genes, future perspectives may be uncovered; (2) Methods: RNA-seq data for serous ovarian cancer were downloaded from The Cancer Genome Atlas an...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Mingjun, Mullikin, Heather, Hester, Anna, Czogalla, Bastian, Heidegger, Helene, Vilsmaier, Theresa, Vattai, Aurelia, Chelariu-Raicu, Anca, Jeschke, Udo, Trillsch, Fabian, Mahner, Sven, Kaltofen, Till
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731240/
https://www.ncbi.nlm.nih.gov/pubmed/33271935
http://dx.doi.org/10.3390/ijms21239169
_version_ 1783621860463738880
author Zheng, Mingjun
Mullikin, Heather
Hester, Anna
Czogalla, Bastian
Heidegger, Helene
Vilsmaier, Theresa
Vattai, Aurelia
Chelariu-Raicu, Anca
Jeschke, Udo
Trillsch, Fabian
Mahner, Sven
Kaltofen, Till
author_facet Zheng, Mingjun
Mullikin, Heather
Hester, Anna
Czogalla, Bastian
Heidegger, Helene
Vilsmaier, Theresa
Vattai, Aurelia
Chelariu-Raicu, Anca
Jeschke, Udo
Trillsch, Fabian
Mahner, Sven
Kaltofen, Till
author_sort Zheng, Mingjun
collection PubMed
description (1) Background: Biomarkers might play a significant role in predicting the clinical outcomes of patients with ovarian cancer. By analyzing lipid metabolism genes, future perspectives may be uncovered; (2) Methods: RNA-seq data for serous ovarian cancer were downloaded from The Cancer Genome Atlas and Gene Expression Omnibus databases. The non-negative matrix factorization package in programming language R was used to classify molecular subtypes of lipid metabolism genes and the limma package in R was performed for functional enrichment analysis. Through lasso regression, we constructed a multi-gene prognosis model; (3) Results: Two molecular subtypes were obtained and an 11-gene signature was constructed (PI3, RGS, ADORA3, CH25H, CCDC80, PTGER3, MATK, KLRB1, CCL19, CXCL9 and CXCL10). Our prognostic model shows a good independent prognostic ability in ovarian cancer. In a nomogram, the predictive efficiency was notably superior to that of traditional clinical features. Related to known models in ovarian cancer with a comparable amount of genes, ours has the highest concordance index; (4) Conclusions: We propose an 11-gene signature prognosis prediction model based on lipid metabolism genes in serous ovarian cancer.
format Online
Article
Text
id pubmed-7731240
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77312402020-12-12 Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile Zheng, Mingjun Mullikin, Heather Hester, Anna Czogalla, Bastian Heidegger, Helene Vilsmaier, Theresa Vattai, Aurelia Chelariu-Raicu, Anca Jeschke, Udo Trillsch, Fabian Mahner, Sven Kaltofen, Till Int J Mol Sci Article (1) Background: Biomarkers might play a significant role in predicting the clinical outcomes of patients with ovarian cancer. By analyzing lipid metabolism genes, future perspectives may be uncovered; (2) Methods: RNA-seq data for serous ovarian cancer were downloaded from The Cancer Genome Atlas and Gene Expression Omnibus databases. The non-negative matrix factorization package in programming language R was used to classify molecular subtypes of lipid metabolism genes and the limma package in R was performed for functional enrichment analysis. Through lasso regression, we constructed a multi-gene prognosis model; (3) Results: Two molecular subtypes were obtained and an 11-gene signature was constructed (PI3, RGS, ADORA3, CH25H, CCDC80, PTGER3, MATK, KLRB1, CCL19, CXCL9 and CXCL10). Our prognostic model shows a good independent prognostic ability in ovarian cancer. In a nomogram, the predictive efficiency was notably superior to that of traditional clinical features. Related to known models in ovarian cancer with a comparable amount of genes, ours has the highest concordance index; (4) Conclusions: We propose an 11-gene signature prognosis prediction model based on lipid metabolism genes in serous ovarian cancer. MDPI 2020-12-01 /pmc/articles/PMC7731240/ /pubmed/33271935 http://dx.doi.org/10.3390/ijms21239169 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zheng, Mingjun
Mullikin, Heather
Hester, Anna
Czogalla, Bastian
Heidegger, Helene
Vilsmaier, Theresa
Vattai, Aurelia
Chelariu-Raicu, Anca
Jeschke, Udo
Trillsch, Fabian
Mahner, Sven
Kaltofen, Till
Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile
title Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile
title_full Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile
title_fullStr Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile
title_full_unstemmed Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile
title_short Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile
title_sort development and validation of a novel 11-gene prognostic model for serous ovarian carcinomas based on lipid metabolism expression profile
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731240/
https://www.ncbi.nlm.nih.gov/pubmed/33271935
http://dx.doi.org/10.3390/ijms21239169
work_keys_str_mv AT zhengmingjun developmentandvalidationofanovel11geneprognosticmodelforserousovariancarcinomasbasedonlipidmetabolismexpressionprofile
AT mullikinheather developmentandvalidationofanovel11geneprognosticmodelforserousovariancarcinomasbasedonlipidmetabolismexpressionprofile
AT hesteranna developmentandvalidationofanovel11geneprognosticmodelforserousovariancarcinomasbasedonlipidmetabolismexpressionprofile
AT czogallabastian developmentandvalidationofanovel11geneprognosticmodelforserousovariancarcinomasbasedonlipidmetabolismexpressionprofile
AT heideggerhelene developmentandvalidationofanovel11geneprognosticmodelforserousovariancarcinomasbasedonlipidmetabolismexpressionprofile
AT vilsmaiertheresa developmentandvalidationofanovel11geneprognosticmodelforserousovariancarcinomasbasedonlipidmetabolismexpressionprofile
AT vattaiaurelia developmentandvalidationofanovel11geneprognosticmodelforserousovariancarcinomasbasedonlipidmetabolismexpressionprofile
AT chelariuraicuanca developmentandvalidationofanovel11geneprognosticmodelforserousovariancarcinomasbasedonlipidmetabolismexpressionprofile
AT jeschkeudo developmentandvalidationofanovel11geneprognosticmodelforserousovariancarcinomasbasedonlipidmetabolismexpressionprofile
AT trillschfabian developmentandvalidationofanovel11geneprognosticmodelforserousovariancarcinomasbasedonlipidmetabolismexpressionprofile
AT mahnersven developmentandvalidationofanovel11geneprognosticmodelforserousovariancarcinomasbasedonlipidmetabolismexpressionprofile
AT kaltofentill developmentandvalidationofanovel11geneprognosticmodelforserousovariancarcinomasbasedonlipidmetabolismexpressionprofile